Response to: Comment on “Nivolumab adjuvant to chemo-radiation in localized muscle-invasive urothelial cancer: primary analysis of a multicenter, single-arm, phase II, investigator-initiated trial (NEXT)”
Saved in:
| Main Authors: | Sumati Gupta, Umang Swami, Gliceida M Galarza Fortuna |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMJ Publishing Group
2025-05-01
|
| Series: | Journal for ImmunoTherapy of Cancer |
| Online Access: | https://jitc.bmj.com/content/13/5/e012378.full |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Comment on “Nivolumab adjuvant to chemo-radiation in localized muscle-invasive urothelial cancer: primary analysis of a multicenter, single-arm, phase II, investigator-initiated trial (NEXT)”
by: Xin Rui, et al.
Published: (2025-04-01) -
Effectiveness and safety of pembrolizumab, nivolumab, and atezolizumab as adjuvant therapy for high-risk muscle-invasive urothelial carcinoma: an indirect comparison
by: Wei Chen, et al.
Published: (2025-01-01) -
The next steps for chemo-optimization in lung cancer treatment
by: Li Feng, et al.
Published: (2025-01-01) -
PLANNING PHASE 2 MULTICENTER RANDOMIZED TRIAL OF NEOADJUVANT CHEMO-RADIOTHERAPY FOLLOWED BY D2 GASTRECTOMY AND ADJUVANT CHEMOTHERAPY FOR LOCALLY ADVANCED GASTRIC CANCER
by: V. Yu. Skoropad, et al.
Published: (2016-07-01) -
Trends in the use and efficacy of adjuvant immunotherapy in muscle-invasive urothelial carcinoma
by: Shingo Hatakeyama, et al.
Published: (2025-07-01)